Triptans for Migraine Management in Adolescents

Authors

  • Paul Winner DO, FAAN

    1. From the Premier Research Institute, Palm Beach Headache Center, West Palm Beach, Florida and Nova Southeastern University, Fort Lauderdale, Florida.
    Search for more papers by this author

Address all correspondence to Dr. Paul Winner, Premier Research Institute, Palm Beach Headache Center, 5205 Greenwood Avenue, West Palm Beach, FL 33407.

Abstract

Objective.—To review triptan efficacy and tolerability data for adolescent migraine sufferers to assist clinicians in selecting triptans for this age group.

Background.—Migraine is a common cause of headache among adolescents. To date, no medications, including those with proven headache relief in adults, have been approved for treatment of migraine in adolescents.

Methods.—Recent triptan clinical trials conducted in adolescent migraine sufferers 12 to 17 years of age were reviewed and results were summarized.

Results.—The success of individual triptan clinical trials conducted in adolescent appears related to time to treatment (1.9 to 6 hours), placebo response (25% to 57%), and day of the week (weekday versus weekend). Overall, triptan tolerability in adolescents is similar to that reported in adults.

Conclusion.—Study results suggest that the triptan class of antimigraine drugs may effectively alleviate migraine in adolescents. Future research should address placebo response and earlier treatment paradigms.

Ancillary